Clinical Report: Prognostic Genes in Clear Cell Renal Cell Carcinoma

Overview

This study identifies eight prognostic genes linked to clear cell renal cell carcinoma (ccRCC) through whole transcriptome sequencing.

Background

Clear cell renal cell carcinoma (ccRCC) accounts for 80-90% of kidney cancer cases and poses significant treatment challenges, including metastatic recurrence and resistance to therapies. Identifying prognostic biomarkers is important for patient management and therapeutic strategies. This study leverages whole transcriptome sequencing to uncover gene expression patterns.

Data Highlights

Key Findings

• Eight prognostic genes were identified: IFNG, CXCL13, KLRK1, LAG3, ITGAX, TNFRSF9, CD2, CD8B.
• These genes are enriched in immune-related pathways, particularly antigen processing and presentation.
• A risk stratification model was constructed based on the identified genes.
• RT-qPCR validation confirmed elevated expression of IFNG, LAG3, TNFRSF9, and CD8B in ccRCC patients compared to controls (p < 0.05).
• Potential targeted drugs were predicted, including amitriptyline hydrochloride and rituximab, with noted binding affinities for ITGAX and KLRK1.

Clinical Implications

Further validation in clinical settings is necessary to establish the utility of the identified gene signature.

Conclusion

This study presents an eight-gene signature that is involved in the tumor immune microenvironment in ccRCC.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. Author(s)/Org, Source, Year -- Title
9. Author(s)/Org, Source, Year -- Title
10. Author(s)/Org, Source, Year -- Title
11. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2026.pdf
12. Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma | Cancer Biomarkers | JAMA Network Open | JAMA Network
13. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial - PMC
14. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
15. Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). | Journal of Clinical Oncology
16. Convergent genomic and molecular features predict risk of metachronous metastasis in clear cell renal cell carcinoma | Communications Medicine